Shanghai, China, 1 August 2022 — Cathbot (Shanghai) Robot Co., Ltd. (“Shanghai Cathbot™”), a joint venture between Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort® MedBot™”) and French company Robocath S.A.S (Robocath), recently announced the completion of the clinical trial for R-ONE™, a vascular interventional surgical robot, making R-ONE™ the first robotic system for vascular intervention to have completed a multicenter clinical trial in China.
During the trial, R-ONE™ was used in a variety of difficult and complex cases such as double-vessel lesions, long diffuse lesions, distorted vascular lesions with large angle kinking and poor coaxiality, calcified lesions, ectopic opening, and pseudo-occlusion. The reliability and stability of R-ONE™ was verified by multiple three-consecutive percutaneous coronary intervention (PCI) procedures carried out in various medical centers, laying an important foundation for the development of more precise, intelligent, and minimally invasive vascular intervention procedures.
All the medical experts who participated in the clinical trial were impressed by the precision, efficiency, safety, and reliability R-ONE™ demonstrated in clinical application. Prof. Yundai Chen, Director of the Department of Cardiology at 301 Hospital, Beijing, China, commented: “I am deeply impressed by the accuracy and quick learning curve of R-ONE™. Not only can it complete the positioning of the balloon and stent catheter precisely, but also enables the simultaneous operation of two guidewires, which makes it easier for them to pass through the diseased vessels, hence suitable for complex lesions such as tortuous, calcified, and ectopic openings. This could reduce the risk of intraoperative and postoperative complications, which would benefit both patients and operators.”
Dr Philippe Bencteux, Chairman and Founder of Robocath, stated: “The successful completion of the clinical trial is a crucial milestone in the process of bringing R-ONE™ to market. It is the first PCI robotic multicenter trial completed in China. The multicenter clinical trial across different regions has validated the product's ease of use, efficacy and safety. I am very impressed with the commitment of the Cathbot team and the team of researchers. They worked very hard to make it happen on time and to maintain our strategic plans despite the impact of the pandemic. I sincerely thank all of them. Our greatest global ambition is to be able to better treat cardiovascular diseases. R-ONE™ will allow the medical staff to work safely while bringing precision to the intervention. We look forward to the publication of the results of this study soon, which will undoubtedly verify the multiple advantages of the R-ONE™ robotic solution in terms of ease of use, shortened procedure time and reduced radiation exposure. This is the solid first step to the commercialization of R-ONE™ in China.”
Dr Chao He, President of MicroPort® MedBot™, said: “The completion of the multicenter clinical trial for the R-ONE™ Vascular Interventional Surgical Robot is a major milestone for MicroPort® MedBot™ in the pan-vascular intervention field. It is of great significance in driving the development of more precise and intelligent vascular interventions. In the future, robots for vascular interventions will be equipped with 5G and AI technologies. They will accomplish more breakthroughs when combined with angiography and hemodynamic monitoring and other technologies. Meanwhile, with the advantage of group-based operation, MicroPort® MedBot™ will partner with more academic experts nationwide to promote high-quality medical resources to primary hospitals, and will provide more patients with precise, intelligent, and inclusive robotic surgical solutions.”
About MicroPort® MedBot™
Founded in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort® MedBot™”, stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, electrical engineering, image-based navigation and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of super intelligent surgery.
More information is available at www.medbotsurgical.com.